This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Position statements: ESPGHAN

The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) is a European medical association focused on the gastrointestinal health of children1

The ESPGHAN IBD Porto group is a group of experts who generate collaborative international research on the diagnosis and management of IBD in children2

The ESPGHAN IBD Porto group released an updated position statement in 2019 that supports the use of INFLECTRA® (CT-P13*/infliximab) in appropriate paediatric patients with IBD3

“There are sufficient data (by extrapolation from different indications, adult data and limited paediatric data) to state that in children with IBD who are indicated for infliximab treatment, CT-P13 is an efficacious alternative to the originator infliximab for induction, and maintenance, of remission”3“A switch from the originator infliximab to CT-P13 may be considered in children with IBD in clinical remission, following at least 3 induction infusions”3
CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.IBD, Inflammatory bowel disease.

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:ESPGHAN web site. What we do. Available at: Accessed May 2023.ESPGHAN web site. Paediatric IBD Porto & Interest Group. Available at: Accessed May Ridder L, et al. J Pediatr Gastroenterol Nutr 2019;68(1):144-53.
Position statements
Support & Resources

Pfizer has a range of resources available to support you and your patients

Explore Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0146 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0784. June 2024